News related to Erbitux (Cetuximab) and/or conditions it is approved for
Overall Survival In 1st-line NSCLC Reaches 15 Months With Erbitux, Merck Serrono Informs
Source: Lung Cancer News From Medical News Today [2008.11.14]
Data presented today at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology show that patients with non-small cell lung cancer (NSCLC) who were given Erbitux® (cetuximab) in addition to a standard 1st-line platinum-based chemotherapy lived significantly longer than those who received chemotherapy alone.1 This effect was more pronounced in patients treated with Erbitux who developed early acne-like rash, resulting in median overall survival of 15 months.
ERBITUX® Supplemental Biologics License Application For First-Line Recurrent Or Metastatic Head And Neck Cancer Accepted For Priority Review By FD
Source: Ear, Nose and Throat News From Medical News Today [2008.10.31]
ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the companies' supplemental Biologics License Application (sBLA) to broaden the indication for ERBITUX® (cetuximab) to include use in combination with platinum-based chemotherapy for the first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Erbitux Extends Life for Head and Neck Cancer Patients
Source: MedicineNet Clinical Trials Specialty [2008.09.11]
Title: Erbitux Extends Life for Head and Neck Cancer Patients
Category: Health News
Created: 9/11/2008 2:00:00 AM
Last Editorial Review: 9/11/2008
Study First To Combine 2 Chemotherapies And 2 Targeted Therapies
Source: Lung Cancer News From Medical News Today [2008.11.14]
The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center.
Colorectal Cancer Treatment Costs Vary Widely (HealthDay)
Source: Y! Health Cancer & Chemotherapy News [2008.11.20]
HealthDay - THURSDAY, Nov. 20 (HealthDay News) -- The cost of treating
colorectal cancer can vary by tens of thousands of dollars per
patient.
Colorectal Cancer Screens Detect Unrecognized Disease (HealthDay)
Source: Y! Health Cancer & Chemotherapy News [2008.11.20]
HealthDay - THURSDAY, Nov. 20 (HealthDay News) -- Colorectal cancer screening
detects 40 percent of cancers and should be carefully planned to be more
effective, say Finnish Cancer Registry researchers.
Lower Socioeconomic Status Decreases Chances Of Early Detection And Survival Of Colorectal Cancer
Source: Colorectal Cancer News From Medical News Today [2008.11.19]
An abstract presented at the American Association for Cancer Research's Seventh Annual International Conference on Frontiers in Cancer Prevention Research shows that lower socioeconomic status reduced the chance of early stage diagnosis and survival of colorectal cancer in Colorado. "Diagnosis of colorectal cancer at an early stage can lead to better survival. Good screening tests for early stage diagnosis of colorectal cancer are available," Alma Palisoc, M.D.
Calcium May Only Protect Against Colorectal Cancer In Presence Of Magnesium
Source: Colorectal Cancer News From Medical News Today [2008.11.18]
High magnesium intake has been associated with low risk of colorectal cancer. Americans have similar average magnesium intake as East Asian populations. If that were all that were involved, observers might expect both groups to have similar risk for colorectal cancer. However, the United States has seen a much higher colorectal cancer incidence rate than East Asian populations.
OncoVAX, Other Vaccines Provide Hope For Colorectal Cancer Treatment, Prevention
Source: Colorectal Cancer News From Medical News Today [2008.11.17]
Propelled by advances in molecular biology, the treatment of colorectal cancer is on the verge of dramatic change and a promising future as innovative vaccines will replace chemotherapy. According to a new report from Kalorama Information, "Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis," this market, lead by OncoVAX, is poised for unprecedented growth, creating countless opportunities for market participants.
Advanced Metastatic Colorectal Cancer - FUSILEV™ Receives Unique, Product-Specific J-Code From The CMS, USA
Source: Colorectal Cancer News From Medical News Today [2008.11.11]
Spectrum Pharmaceuticals, Inc., (NasdaqGM:SPPI) announced today that the Centers for Medicare and Medicaid Services (CMS), under the Medicare Part B benefit, has assigned a unique, product-specific billing code, or J-code, for FUSILEV™ (levoleucovorin). FUSILEV™ is the only commercially available formulation comprised only of the pharmacologically active isomer of leucovorin.
Huge Variation In Cost Of Treating Colorectal Cancer
Source: Colorectal Cancer News From Medical News Today [2008.11.10]
The cost of treating colorectal cancer varies widely, with newer, life-extending therapies sometimes costing tens of thousands of dollars more than older agents, according to a study led by a team of researchers in the Duke Comprehensive Cancer Center. "The total cost of chemotherapy to treat colorectal cancer may differ by as much as $36,999 per patient, depending on the regimen," said Gary Lyman, M.D.
NCCN Updates Guidelines For Colorectal Cancer
Source: Colorectal Cancer News From Medical News Today [2008.11.05]
The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Guidelines on Colon and Rectal Cancers. These changes reflect leading developments in the treatment of patients with colon and rectal cancers and represent the standard of care in oncology in both community and academic settings.
California Colorectal Cancer Coalition Holds Its First Community Forum To Save Lives By Promoting And Advocating For Colorectal Cancer Screening
Source: Colorectal Cancer News From Medical News Today [2008.11.04]
To prevent more deaths and suffering from the third most common cancer in California, the California Colorectal Cancer Coalition (C4) http://cacoloncancer.org/ recently held its first community forum, calling for a 10 percent increase in the rates of colorectal cancer screening.
Colorectal Cancer Risk Increased By Metabolic Syndrome
Source: Cholesterol News From Medical News Today [2008.10.07]
In a large U.S. population-based study presented at the 73rd Annual Scientific Meeting of the American College of Gastroenterology, metabolic syndrome patients had a 75 percent higher risk of colorectal cancer compared to those without metabolic syndrome. Dr. Donald Garrow and Dr.
Recommended Follow-Up Care Lacking In Many Colorectal Cancer Survivors
Source: Compliance News From Medical News Today [2008.09.09]
A new analysis reveals that fewer than half of older patients successfully treated for colorectal cancer receive the recommended screening schedule to detect any recurrence of cancer. The study, appearing in the October 15, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society, indicates poor compliance to recommended monitoring of colorectal cancer survivors could affect survival.
Antidepressants might reduce risk of colorectal cancer
Source: The Doctors Lounge - Psychiatry
Use of serotonin reuptake inhibitors (SSRI) might inhibit the growth of colorectal tumors according to The Lancet Oncology.
Plymouth Hospitals To Lead Cancer Surgery Training Programme, England
Source: Colorectal Cancer News From Medical News Today [2008.11.17]
Plymouth Hospitals NHS Trust has been chosen to co-ordinate the national programme for the training of existing consultants in advanced keyhole surgery for the treatment of bowel cancer. The Department of Health has appointed Consultant General Surgeon, Mr Mark Coleman as the National Clinical Lead for the Laparoscopic Colorectal Cancer Surgery Training Programme.
Circulating Tumor Cells Predict Survival Benefit From Treatment In Metastatic Castration-Resistant Prostate Cancer
Source: Prostate / Prostate Cancer News From Medical News Today [2008.11.10]
UroToday.com - In the October 1, 2008 issue of Clinical Cancer Research, Dr. Johann de Bono and colleagues presented exciting data indicating that circulating tumor cells (CTC) predict overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). CTC using the commercially available CellSearch is approved by the FDA as a prognostic indicator for patients with metastatic breast, prostate, and colorectal cancer.
Half-Broken Gene Is Enough To Cause Cancer
Source: Colorectal Cancer News From Medical News Today [2008.11.04]
Tumour suppressor genes do not necessarily require both alleles to be knocked out before disease phenotypes are expressed. Research published in BioMed Central's new open access journal PathoGenetics reveals that only one allele of SMAD4 has to be damaged to put a person at risk of pancreatic and colorectal cancer.
Increased Cancer Risk Following Liver Transplant
Source: Colorectal Cancer News From Medical News Today [2008.11.04]
A new Canadian study comparing cancer rates of liver transplant patients to those of the general population has found that transplant recipients face increased risks of developing cancer, especially non-Hodgkin's lymphoma and colorectal cancer. Risks were more pronounced during the first year of follow-up and among younger transplant recipients. These findings are published in the November issue of Liver Transplantation, a journal by John Wiley & Sons.
Biohit Launches New Quick Tests For Fecal Occult Blood
Source: Colorectal Cancer News From Medical News Today [2008.11.03]
Biohit is extending its range of diagnostic tests for gastrointestinal diseases with ColonView Hb and Hb/Hp quick tests, which are intended to aid early diagnosis and prevention of colorectal cancer. ColonView testing can be used for simple and cost-effective identification of patients with fecal occult blood, which is a well-known marker for colorectal cancer and pre-cancerous large adenomas.
|
